Molecular Imaging of Angiogenesis in Cardiac Regeneration

Current Cardiovascular Imaging Reports

Volumn 9, Issue 10, 2016, Pages

  Mandic, Ljubica ^a   Traxler, Denise ^a   Gugerell, Alfred ^a   Zlabinger, Katrin ^a   Lukovic, Dominika ^a   Pavo, Noemi ^a   Goliasch, Georg ^a   Spannbauer, Andreas ^a   Winkler, Johannes ^a   Gyöngyösi, Mariann ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Angiogenesis; Integrins; Molecular imaging; Myocardial infarction; Myocardial regeneration; Radiotracers

Indexed keywords

BROMINE 76; COPPER 64; ENDOGLIN; FIBROBLAST GROWTH FACTOR; FLUORINE 18; GADOLINIUM; INDIUM 111; INTEGRIN; MICROSOMAL AMINOPEPTIDASE; TECHNETIUM 99M; VASCULOTROPIN; ZIRCONIUM 89;

ANGIOGENESIS; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; BLOOD FLOW; CARDIAC REGENERATION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR IMAGING; MULTIMODAL IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; REGENERATION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84986596560     PISSN: 19419066     EISSN: 19419074     Source Type: Journal    
DOI: 10.1007/s12410-016-9389-6     Document Type: Review

References (101)

1. Cochain C, Channon KM, Silvestre JS. Angiogenesis in the infarcted myocardium. Antioxid Redox Signal. 2013;18(9):1100–13. doi:10.1089/ars.2012.4849.
2. Shah AM, Mann DL. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet. 2011;378(9792):704–12. doi:10.1016/S0140-6736(11)60894-5.
3. Battegay EJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med. 1995;73(7):333–46.
4. Meoli DF, Sadeghi MM, Krassilnikova S, Bourke BN, Giordano FJ, Dione DP, et al. Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest. 2004;113(12):1684–91. doi:10.1172/JCI20352.
5. Uchida Y, Yanagisawa-Miwa A, Nakamura F, Yamada K, Tomaru T, Kimura K, et al. Angiogenic therapy of acute myocardial infarction by intrapericardial injection of basic fibroblast growth factor and heparin sulfate: an experimental study. Am Heart J. 1995;130(6):1182–8.
6. Gyöngyösi M, Wojakowski W, Lemarchand P, Lunde K, Tendera M, Bartunek J, et al. Meta-analysis of cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res. 2015. doi:10.1161/circresaha.116.304346.
7. Scimia MC, Gumpert AM, Koch WJ. Cardiovascular gene therapy for myocardial infarction. Expert Opin Biol Ther. 2014;14(2):183–95. doi:10.1517/14712598.2014.866085.
8. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011;146(6):873–87. doi:10.1016/j.cell.2011.08.039.
9. Dissoki S, Abourbeh G, Salnikov O, Mishani E, Jacobson O. PET molecular imaging of angiogenesis with a multiple tyrosine kinase receptor-targeted agent in a rat model of myocardial infarction. Mol Imaging Biol. 2015;17(2):222–30. doi:10.1007/s11307-014-0790-8.
10. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–307. doi:10.1038/nature10144.
11. Frangogiannis NG. The mechanistic basis of infarct healing. Antioxid Redox Signal. 2006;8(11-12):1907–39. doi:10.1089/ars.2006.8.1907.
12. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35(3):569–82.
13. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest. 2005;115(8):2108–18. doi:10.1172/JCI24682.
14. Silvestre JS, Smadja DM, Levy BI. Postischemic revascularization: from cellular and molecular mechanisms to clinical applications. Physiol Rev. 2013;93(4):1743–802. doi:10.1152/physrev.00006.2013.
15. Jivraj N, Phinikaridou A, Shah AM, Botnar RM. Molecular imaging of myocardial infarction. Basic Res Cardiol. 2014;109(1):397. doi:10.1007/s00395-013-0397-2.
16. Stacy MR, Sinusas AJ. Emerging imaging modalities in regenerative medicine. Curr Pathobiol Rep. 2015;3(1):27–36. doi:10.1007/s40139-015-0073-3.
17. Ripa RS, Kjaer A. Imaging atherosclerosis with hybrid positron emission tomography/magnetic resonance imaging. Biomed Res Int. 2015;2015:914516. doi:10.1155/2015/914516.
18. Stacy MR, Maxfield MW, Sinusas AJ. Targeted molecular imaging of angiogenesis in PET and SPECT: a review. Yale J Biol Med. 2012;85(1):75–86.
19. Naumova AV, Modo M, Moore A, Murry CE, Frank JA. Clinical imaging in regenerative medicine. Nat Biotechnol. 2014;32(8):804–18. doi:10.1038/nbt.2993.
20. 18 F-Alfatide II was used to demonstrate increased myocardial angiogenesis in rats treated with VEGF and/or BMSCs.
21. Li X, Heber D, Rausch I, Beitzke D, Mayerhoefer ME, Rasul S, et al. Quantitative assessment of atherosclerotic plaques on F-FDG PET/MRI: comparison with a PET/CT hybrid system. Eur J Nucl Med Mol Imaging. 2016. doi:10.1007/s00259-016-3308-6.
22. Ratib O, Nkoulou R. Potential applications of PET/MR imaging in cardiology. J Nucl Med. 2014;55(Supplement 2):40S–6. doi:10.2967/jnumed.113.129262.
23. Stacy MR, Paeng JC, Sinusas AJ. The role of molecular imaging in the evaluation of myocardial and peripheral angiogenesis. Ann Nucl Med. 2015;29(3):217–23. doi:10.1007/s12149-015-0961-y.
24. Lee JS, Kim JH. Recent advances in hybrid molecular imaging systems. Semin Musculoskelet Radiol. 2014;18(2):103–22. doi:10.1055/s-0034-1371014.
25. Constantine G, Shan K, Flamm SD, Sivananthan MU. Role of MRI in clinical cardiology. Lancet. 2004;363(9427):2162–71. doi:10.1016/S0140-6736(04)16509-4.
26. Mulder WJ, Strijkers GJ, Habets JW, Bleeker EJ, van der Schaft DW, Storm G, et al. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J. 2005;19(14):2008–10. doi:10.1096/fj.05-4145fje.
27. Schmieder AH, Winter PM, Caruthers SD, Harris TD, Williams TA, Allen JS, et al. Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn Reson Med. 2005;53(3):621–7. doi:10.1002/mrm.20391.
28. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med. 1998;4(5):623–6.
29. Zhang C, Jugold M, Woenne EC, Lammers T, Morgenstern B, Mueller MM, et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res. 2007;67(4):1555–62. doi:10.1158/0008-5472.CAN-06-1668.
30. Leung K. Cyclo(Arg-Gly-Asp-D-Try-Glu) conjugated to ultrasmall superparamagnetic iron oxide nanoparticles. Bethesda (MD): Molecular Imaging and Contrast Agent Database (MICAD); 2004.
31. Yang Y, Yang Y, Yanasak N, Schumacher A, Hu TC. Temporal and noninvasive monitoring of inflammatory-cell infiltration to myocardial infarction sites using micrometer-sized iron oxide particles. Magn Reson Med. 2010;63(1):33–40. doi:10.1002/mrm.22175.
32. Singh N, Jenkins GJS, Asadi R, Doak SH. Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Reviews. 2010; 1:10.3402/nano.v3401i3400.5358. doi:10.3402/nano.v1i0.5358.
33. Smith AH, Fujii H, Kuliszewski MA, Leong-Poi H. Contrast ultrasound and targeted microbubbles: diagnostic and therapeutic applications for angiogenesis. J Cardiovasc Transl Res. 2011;4(4):404–15. doi:10.1007/s12265-011-9282-2.
34. Xie J, Liao Y, Yang L, Wu J, Liu C, Xuan W, et al. Ultrasound molecular imaging of angiogenesis induced by mutant forms of hypoxia-inducible factor-1alpha. Cardiovasc Res. 2011;92(2):256–66. doi:10.1093/cvr/cvr229.
35. Payen T, Dizeux A, Baldini C, Le Guillou-Buffello D, Lamuraglia M, Comperat E, et al. VEGFR2-targeted contrast-enhanced ultrasound to distinguish between two anti-angiogenic treatments. Ultrasound Med Biol. 2015;41(8):2202–11. doi:10.1016/j.ultrasmedbio.2015.04.010.
36. Kim JE, Kalimuthu S, Ahn BC. In vivo cell tracking with bioluminescence imaging. Nucl Med Mol Imaging. 2015;49(1):3–10. doi:10.1007/s13139-014-0309-x.
37. Baker M. Whole-animal imaging: the whole picture. Nature. 2010;463(7283):977–80. doi:10.1038/463977a.
38. Ahn BC. Applications of molecular imaging in drug discovery and development process. Curr Pharm Biotechnol. 2011;12(4):459–68.
39. Nguyen PK, Lan F, Wang Y, Wu JC. Imaging: guiding the clinical translation of cardiac stem cell therapy. Circ Res. 2011;109(8):962–79. doi:10.1161/CIRCRESAHA.111.242909.
40. Blankstein R, Di Carli MF. Integration of coronary anatomy and myocardial perfusion imaging. Nat Rev Cardiol. 2010;7(4):226–36. doi:10.1038/nrcardio.2010.15.
41. Gaemperli O, Kaufmann PA, Alkadhi H. Cardiac hybrid imaging. Eur J Nucl Med Mol Imaging. 2014;41 Suppl 1:S91–103. doi:10.1007/s00259-013-2566-9.
42. Fricke E, Fricke H, Weise R, Kammeier A, Hagedorn R, Lotz N, et al. Attenuation correction of myocardial SPECT perfusion images with low-dose CT: evaluation of the method by comparison with perfusion PET. J Nucl Med. 2005;46(5):736–44.
43. Brown ER, Kronmal RA, Bluemke DA, Guerci AD, Carr JJ, Goldin J, et al. Coronary calcium coverage score: determination, correlates, and predictive accuracy in the Multi-Ethnic Study of Atherosclerosis. Radiology. 2008;247(3):669–75. doi:10.1148/radiol.2473071469.
44. Budoff MJ, Shaw LJ, Liu ST, Weinstein SR, Mosler TP, Tseng PH, et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol. 2007;49(18):1860–70. doi:10.1016/j.jacc.2006.10.079.
45. Henzlova MJ, Duvall WL. The future of SPECT MPI: time and dose reduction. J Nucl Cardiol. 2011;18(4):580–7. doi:10.1007/s12350-011-9401-0.
46. Palyo R, Sinusas A, Liu YH. High-sensitivity and high-resolution SPECT/CT systems provide substantial dose reduction without compromising quantitative precision for assessment of myocardial perfusion or function. J Nucl Med. 2016. doi:10.2967/jnumed.115.164632.
47. Joshi NV, Vesey AT, Williams MC, Shah AS, Calvert PA, Craighead FH, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet. 2014;383(9918):705–13. doi:10.1016/S0140-6736(13)61754-7.
48. Mazurek T, Kobylecka M, Zielenkiewicz M, Kurek A, Kochman J, Filipiak KJ, et al. PET/CT evaluation of F-FDG uptake in pericoronary adipose tissue in patients with stable coronary artery disease: Independent predictor of atherosclerotic lesions’ formation? J Nucl Cardiol. 2016. doi:10.1007/s12350-015-0370-6.
49. Iagaru A, Gambhir SS. Imaging tumor angiogenesis: the road to clinical utility. AJR Am J Roentgenol. 2013;201(2):W183–91. doi:10.2214/AJR.12.8568.
50. Laitinen I, Notni J, Pohle K, Rudelius M, Farrell E, Nekolla SG, et al. Comparison of cyclic RGD peptides for alphavbeta3 integrin detection in a rat model of myocardial infarction. EJNMMI Res. 2013;3(1):38. doi:10.1186/2191-219x-3-38.
51. Menichetti L, Kusmic C, Panetta D, Arosio D, Petroni D, Matteucci M, et al. MicroPET/CT imaging of alphavbeta(3) integrin via a novel (6)(8)Ga-NOTA-RGD peptidomimetic conjugate in rat myocardial infarction. Eur J Nucl Med Mol Imaging. 2013;40(8):1265–74. doi:10.1007/s00259-013-2432-9.
52. 3 and immunohistochemistical stainings.
53. Hendrikx G, De Saint-Hubert M, Dijkgraaf I, Bauwens M, Douma K, Wierts R, et al. Molecular imaging of angiogenesis after myocardial infarction by (111)In-DTPA-cNGR and (99m)Tc-sestamibi dual-isotope myocardial SPECT. EJNMMI Res. 2015;5:2. doi:10.1186/s13550-015-0081-7.
54. Orbay H, Zhang Y, Valdovinos HF, Song G, Hernandez R, Theuer CP, et al. Positron emission tomography imaging of CD105 expression in a rat myocardial infarction model with (64)Cu-NOTA-TRC105. Am J Nucl Med Mol Imaging. 2013;4(1):1–9.
55. 3 is feasable.
56. Melemenidis S, Jefferson A, Ruparelia N, Akhtar AM, Xie J, Allen D, et al. Molecular magnetic resonance imaging of angiogenesis in vivo using polyvalent cyclic RGD-iron oxide microparticle conjugates. Theranostics. 2015;5(5):515–29. doi:10.7150/thno.10319. This study on tumour angiogenesis in mice shows for the first time representative in vivo angiogenesis imaging using RGD-targeted MPIOs in MRI.
57. 1 was demonstrated to be more specific for activated endothelial cells with however no decline in affinity.
58. Dobrucki LW, de Muinck ED, Lindner JR, Sinusas AJ. Approaches to multimodality imaging of angiogenesis. J Nucl Med. 2010. doi:10.2967/jnumed.110.074963.
59. Luo BH, Springer TA. Integrin structures and conformational signaling. Curr Opin Cell Biol. 2006;18(5):579–86. doi:10.1016/j.ceb.2006.08.005.
60. Humphries MJ. Integrin cell adhesion receptors and the concept of agonism. Trends Pharmacol Sci. 2000;21(1):29–32.
61. Horton MA. The alpha v beta 3 integrin “vitronectin receptor”. Int J Biochem Cell Biol. 1997;29(5):721–5.
62. Higuchi T, Bengel FM, Seidl S, Watzlowik P, Kessler H, Hegenloh R, et al. Assessment of alphavbeta3 integrin expression after myocardial infarction by positron emission tomography. Cardiovasc Res. 2008;78(2):395–403. doi:10.1093/cvr/cvn033.
63. Bader BL, Rayburn H, Crowley D, Hynes RO. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell. 1998;95(4):507–19.
64. Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X, et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med. 2002;8(1):27–34. doi:10.1038/nm0102-27.
65. Reynolds AR, Reynolds LE, Nagel TE, Lively JC, Robinson SD, Hicklin DJ, et al. Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice. Cancer Res. 2004;64(23):8643–50. doi:10.1158/0008-5472.CAN-04-2760.
66. Atkinson SJ, Ellison TS, Steri V, Gould E, Robinson SD. Redefining the role(s) of endothelial alphavbeta3-integrin in angiogenesis. Biochem Soc Trans. 2014;42(6):1590–5. doi:10.1042/BST20140206.
67. Mittra ES, Goris ML, Iagaru AH, Kardan A, Burton L, Berganos R, et al. Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging alpha(v)beta(3) integrin levels. Radiology. 2011;260(1):182–91. doi:10.1148/radiol.11101139.
68. Beer AJ, Lorenzen S, Metz S, Herrmann K, Watzlowik P, Wester HJ, et al. Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med. 2008;49(1):22–9. doi:10.2967/jnumed.107.045864.
69. Lang L, Li W, Guo N, Ma Y, Zhu L, Kiesewetter DO, et al. Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem. 2011;22(12):2415–22. doi:10.1021/bc200197h.
70. Zhu Z, Yin Y, Zheng K, Li F, Chen X, Zhang F, et al. Evaluation of synovial angiogenesis in patients with rheumatoid arthritis using (6)(8)Ga-PRGD2 PET/CT: a prospective proof-of-concept cohort study. Ann Rheum Dis. 2014;73(6):1269–72. doi:10.1136/annrheumdis-2013-204820.
71. Chen X, Liu S, Hou Y, Tohme M, Park R, Bading JR, et al. MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol. 2004;6(5):350–9. doi:10.1016/j.mibio.2004.06.004.
72. Lang L, Li W, Jia HM, Fang DC, Zhang S, Sun X, et al. New methods for labeling RGD peptides with bromine-76. Theranostics. 2011;1:341–53.
73. Jacobson O, Zhu L, Niu G, Weiss ID, Szajek LP, Ma Y, et al. MicroPET imaging of integrin alphavbeta3 expressing tumors using 89Zr-RGD peptides. Mol Imaging Biol. 2011;13(6):1224–33. doi:10.1007/s11307-010-0458-y.
74. Axelsson R, Bach-Gansmo T, Castell-Conesa J, McParland BJ, Study G. An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the alpha v beta 3-selective angiogenesis imaging agent 99mTc-NC100692. Acta Radiol. 2010;51(1):40–6. doi:10.3109/02841850903273974.
75. Jia B, Liu Z, Zhu Z, Shi J, Jin X, Zhao H, et al. Blood clearance kinetics, biodistribution, and radiation dosimetry of a kit-formulated integrin alphavbeta3-selective radiotracer 99mTc-3PRGD 2 in non-human primates. Mol Imaging Biol. 2011;13(4):730–6. doi:10.1007/s11307-010-0385-y.
76. Terry SY, Abiraj K, Frielink C, van Dijk LK, Bussink J, Oyen WJ, et al. Imaging integrin alphavbeta3 on blood vessels with 111In-RGD2 in head and neck tumor xenografts. J Nucl Med. 2014;55(2):281–6. doi:10.2967/jnumed.113.129668.
77. Sherif HM, Saraste A, Nekolla SG, Weidl E, Reder S, Tapfer A, et al. Molecular imaging of early alphavbeta3 integrin expression predicts long-term left-ventricle remodeling after myocardial infarction in rats. J Nucl Med. 2012;53(2):318–23. doi:10.2967/jnumed.111.091652.
78. Notni J, Pohle K, Wester HJ. Be spoilt for choice with radiolabelled RGD peptides: preclinical evaluation of (6)(8)Ga-TRAP(RGD)(3). Nucl Med Biol. 2013;40(1):33–41. doi:10.1016/j.nucmedbio.2012.08.006.
79. Pohle K, Notni J, Bussemer J, Kessler H, Schwaiger M, Beer AJ. 68Ga-NODAGA-RGD is a suitable substitute for (18)F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process. Nucl Med Biol. 2012;39(6):777–84. doi:10.1016/j.nucmedbio.2012.02.006.
80. Gao H, Lang L, Guo N, Cao F, Quan Q, Hu S, et al. PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin targeted tracer (18)F-AlF-NOTA-PRGD2. Eur J Nucl Med Mol Imaging. 2012;39(4):683–92. doi:10.1007/s00259-011-2052-1.
81. Dimastromatteo J, Riou LM, Ahmadi M, Pons G, Pellegrini E, Broisat A, et al. In vivo molecular imaging of myocardial angiogenesis using the αvβ3 integrin-targeted tracer 99mTc-RAFT-RGD. J Nucl Cardiol. 2010;17(3):435–43. doi:10.1007/s12350-010-9191-9.
82. Paeng JC, Bregasi A, Sahul Z, Kalinowski L, Dobrucki LW, Brennan M, et al. Serial reference tissue-based quantitative and volumetric analysis of integrin-targeted angiogenesis imaging: chronic canine model of myocardial infarction. J Nucl Med. 2014;2014(55):1710.
83. Gaertner FC, Kessler H, Wester HJ, Schwaiger M, Beer AJ. Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 1:S126–38. doi:10.1007/s00259-011-2028-1.
84. Hu Q, Wang XY, Kang LK, Wei HM, Xu CM, Wang T, et al. RGD-targeted ultrasound contrast agent for longitudinal assessment of Hep-2 tumor angiogenesis in vivo. PLoS One. 2016;11(2):e0149075. doi:10.1371/journal.pone.0149075.
85. Shelton SE, Lindsey BD, Tsuruta JK, Foster FS, Dayton PA. Molecular acoustic angiography: a new technique for high-resolution superharmonic ultrasound molecular imaging. Ultrasound Med Biol. 2016;42(3):769–81. doi:10.1016/j.ultrasmedbio.2015.10.015.
86. Yan F, Xu X, Chen Y, Deng Z, Liu H, Xu J, et al. A lipopeptide-based alphavbeta(3) integrin-targeted ultrasound contrast agent for molecular imaging of tumor angiogenesis. Ultrasound Med Biol. 2015;41(10):2765–73. doi:10.1016/j.ultrasmedbio.2015.05.023.
87. Leong-Poi H. Molecular imaging using contrast-enhanced ultrasound: evaluation of angiogenesis and cell therapy. Cardiovasc Res. 2009;84(2):190–200. doi:10.1093/cvr/cvp248.
88. Deng Q, Hu B, Cao S, Song HN, Chen JL, Zhou Q. Improving the efficacy of therapeutic angiogenesis by UTMD-mediated Ang-1 gene delivery to the infarcted myocardium. Int J Mol Med. 2015;36(2):335–44. doi:10.3892/ijmm.2015.2226.
89. Nguyen AT, Wrenn SP. Acoustically active liposome-nanobubble complexes for enhanced ultrasonic imaging and ultrasound-triggered drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014;6(3):316–25. doi:10.1002/wnan.1255.
90. Fassler R, Meyer M. Consequences of lack of beta 1 integrin gene expression in mice. Genes Dev. 1995;9(15):1896–908.
91. Tanjore H, Zeisberg EM, Gerami-Naini B, Kalluri R. Beta1 integrin expression on endothelial cells is required for angiogenesis but not for vasculogenesis. Dev Dyn. 2008;237(1):75–82. doi:10.1002/dvdy.21385.
92. Kim S, Bell K, Mousa SA, Varner JA. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol. 2000;156(4):1345–62.
93. Corti A, Curnis F, Arap W, Pasqualini R. The neovasculature homing motif NGR: more than meets the eye. Blood. 2008;112(7):2628–35. doi:10.1182/blood-2008-04-150862.
94. Bhagwat SV, Lahdenranta J, Giordano R, Arap W, Pasqualini R, Shapiro LH. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood. 2001;97(3):652–9.
95. Buehler A, van Zandvoort MA, Stelt BJ, Hackeng TM, Schrans-Stassen BH, Bennaghmouch A, et al. cNGR: a novel homing sequence for CD13/APN targeted molecular imaging of murine cardiac angiogenesis in vivo. Arterioscler Thromb Vasc Biol. 2006;26(12):2681–7. doi:10.1161/01.ATV.0000245807.65714.0b.
96. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279(5349):377–80.
97. Fonsatti E, Sigalotti L, Arslan P, Altomonte M, Maio M. Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies. Curr Cancer Drug Targets. 2003;3(6):427–32.
98. Hong H, Zhang Y, Orbay H, Valdovinos HF, Nayak TR, Bean J, et al. Positron emission tomography imaging of tumor angiogenesis with a (61/64)Cu-labeled F(ab’)(2) antibody fragment. Mol Pharm. 2013;10(2):709–16. doi:10.1021/mp300507r.
99. Zhang Y, Hong H, Severin GW, Engle JW, Yang Y, Goel S, et al. ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with (89)Zr and IRDye 800CW. Am J Transl Res. 2012;4(3):333–46.
100. Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, et al. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci. 2008;121(20):3487–95. doi:10.1242/jcs.016410.
101. Li S, Peck-Radosavljevic M, Koller E, Koller F, Kaserer K, Kreil A, et al. Characterization of 123I-vascular endothelial growth factor–binding sites expressed on human tumour cells: Possible implication for tumour scintigraphy. Int J Cancer. 2001;91(6):789–96. doi:10.1002/1097-0215(200002)9999:9999<::AID-IJC1126>3.0.CO;2-K.